title: Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure.
abstract: OBJECTIVE
  In this study, we examined the effects of long-term therapy with bosentan on the progression of LV dysfunction and remodeling in dogs with moderate HF.
  
  
  BACKGROUND
  Acute intravenous administration of bosentan, a mixed endothelin-1 type A and type B receptor antagonist, was shown to improve left ventricular (LV) function in patients and dogs with heart failure (HF).
  
  
  METHODS
  Left ventricular dysfunction was induced by multiple, sequential intracoronary microembolizations in 14 dogs. Embolizations were discontinued when LV ejection fraction (EF) was between 30% and 40%. Dogs were randomized to three months of therapy with bosentan (30 mg/kg twice daily, n = 7) or no therapy at all (control, n = 7).
  
  
  RESULTS
  In untreated dogs, EF decreased from 35 +/- 1% before initiating therapy to 29 +/- 1% at the end of three months of therapy (p = 0.001), and LV end-diastolic volume (EDV) and end-systolic volume (ESV) increased (EDV: 71 +/- 3 vs. 84 +/- 8 ml, p = 0.08; ESV: 46 +/- 2 vs. 60 +/- 6 ml, p = 0.03). By contrast, in dogs treated with bosentan, EF tended to increase from 34 +/- 2% before initiating therapy to 39 +/- 1% at the end of three months of therapy (p = 0.06), and EDV and ESV decreased (EDV: 75 +/- 3 vs. 71 +/- 4 ml, p = 0.05; ESV: 48 +/- 2 vs. 43 +/- 3 ml, p = 0.01). Furthermore, compared with untreated dogs, dogs treated with bosentan showed significantly less LV cardiomyocyte hypertrophy and LV volume fraction of interstitial fibrosis.
  
  
  CONCLUSIONS
  In dogs with moderate HF, long-term therapy with bosentan prevents the progression of LV dysfunction and attenuates LV chamber remodeling. The findings support the use of mixed endothelin-1 receptor antagonists as adjuncts to the long-term treatment of HF.
authors.affiliation: Department of Medicine, Henry Ford Heart and Vascular Institute, Detroit, Michigan, USA.
authors.forename: T
authors.initials: T
authors.lastname: Mishima
authors.forename: M
authors.initials: M
authors.lastname: Tanimura
authors.forename: G
authors.initials: G
authors.lastname: Suzuki
authors.forename: A
authors.initials: A
authors.lastname: Todor
authors.forename: V G
authors.initials: VG
authors.lastname: Sharov
authors.forename: S
authors.initials: S
authors.lastname: Goldstein
authors.forename: H N
authors.initials: HN
authors.lastname: Sabbah
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D000077300:Bosentan; D018450:Disease Progression; D004285:Dogs; D006333:Heart Failure / Q000473:pathology / Q000503:physiopathology*; D007262:Infusions, Intravenous; D009206:Myocardium / Q000473:pathology; D013318:Stroke Volume / Q000187:drug effects / Q000502:physiology; D013449:Sulfonamides / Q000494:pharmacology*; D018487:Ventricular Dysfunction, Left / Q000473:pathology / Q000503:physiopathology*; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology; D020257:Ventricular Remodeling / Q000187:drug effects* / Q000502:physiology
chemical_list: D000959:Antihypertensive Agents; D013449:Sulfonamides; D000077300:Bosentan